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Background. Tissue transglutaminase (TG2), a cross-linking enzyme, modulates deposition of extracellular matrix protein in
renal fibrosis. This study aimed to examine TG2 and its cross-link product 𝜀(𝛾-glutamyl)-lysine in the Fisher-Lewis rat renal
transplantation (RTx) model of chronic allograft nephropathy (CAN). Materials and Methods. Left renal grafts from male Fisher
and Lewis were transplanted into Lewis rats, generating allografts and isografts, respectively. Blood pressure, renal function, and
proteinuria were monitored for up to 52 weeks. At termination, CAN was assessed in the renal tissue by light and electron
microscopy, TG2 and 𝜀(𝛾-glutamyl)-lysine by immunofluorescence, and the urinary 𝜀(𝛾-glutamyl)-lysine by high performance
liquid chromatography. Results. Compared to the isograft, the allografts were hypertensive, proteinuric, and uraemic and developed
CAN. Extracellular TG2 (glomerulus: 64.55 ± 17.61 versus 2.11 ± 0.17, 𝑃 < 0.001; interstitium: 13.72 ± 1.62 versus 3.19 ± 0.44,
𝑃 < 0.001), 𝜀(𝛾-glutamyl)-lysine (glomerulus: 21.74±2.71 versus 1.98±0.37, 𝑃 < 0.01; interstitium: 37.96±17.06 versus 0.42±0.11,
𝑃 < 0.05), TG2 enzyme activity (1.09±0.13 versus 0.41±0.03 nmol/h/mg protein,𝑃 < 0.05), TG2mRNA (20-fold rise), and urinary
𝜀(𝛾-glutamyl)-lysine (534.2±198.4 nmol/24 h versus 57.2±4.1 nmol/24 h,𝑃 < 0.05) levels were significantly elevated in the allografts
and showed a positive linear correlation with tubulointerstitial fibrosis. Conclusion. CAN was associated with upregulation of renal
TG2 pathway, which has a potential for pharmacological intervention.The elevated urinary 𝜀(𝛾-glutamyl)-lysine, measured for the
first time in RTx, is a potential biomarker of CAN.
1. Introduction
The advantages conferred by renal transplantation (RTx),
such as the improved quality of life [1] and survival, are
continually compromised by graft loss due to development
of chronic allograft nephropathy (CAN), which manifests
with hypertension, proteinuria, and progressive deterioration
of renal function due to interstitial fibrosis (IF), tubular
atrophy (TA), obliterative arteriolopathy, and glomeruloscle-
rosis [2], which is initiated by the interplay of alloantigen-
dependent and alloantigen-independent risk factors [3, 4].
Hypotheses propounded to explain its pathogenesis include
chronic antibody-mediated rejection, input-stress model,
replicative senescence, cytokine excess, cumulative damage,
and oxidative stress [5–11] leading to epithelial-mesenchymal
transdifferentiation (EMT) and the elaboration of the extra-
cellular matrix (ECM) in the tubulointerstitial, glomerular,
and vascular compartments of the kidney [12, 13].
In the early stage of CAN, renal function can be preserved
by control of hypertension [14], proteinuria [15], hyperlipi-
daemia [16], and institution of least nephrotoxic immuno-
suppressive regimens [17]. However, as yet, established CAN
has no treatment due, in part, to irreversible tissue damage at
the time of diagnosis. ECM deposition is a key event in the
development of CAN and targeting graft fibrosis has recently
been proposed as a new focus in organ transplantation [13].
Tissue transglutaminase (TG2) (EC 2.3.2.13) catalyses
Ca+2-dependent, transamidation reactions by the transfer of
acyl groupings from glutamine to lysine residues of ECM
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protein molecules forming a covalent bond, where the cross-
link product, 𝜀(𝛾-glutamyl)-lysine, leads to ECM stabilisation
(Figure 1) [18, 19]. TG2 is activated, following its export from
the cell, by calcium in the extracellular fluid. Activated TG2
accelerates the deposition of ECM components, its cross-
linked products being highly resistant to proteolytic degra-
dation by matrix metalloproteinases (MMPs) [20]. Excessive
expansion of ECM leads to cellular damage mainly from
ischaemia. TG2 is also involved in cellular apoptosis [21].
Significant upregulation of TG2 has previously been observed
in experimental rat models of 5/6 subtotal nephrectomy [21]
and diabetic nephropathy [22] as well as human renal disease
[23] and human RTx biopsies of CAN [24]. Literature search
showed absence of studies of TG2 in animal experimental
models of RTx, hence making it a new tool for interventional
studies in the prevention of CAN. Likewise, there is no record
of estimation of cross-link 𝜀(𝛾-glutamyl)-lysine in the urine
samples in human or animal models of transplantation in
relation to transplant fibrosis.
The aim of the present study was to examine the associ-
ation of TG2 pathway with the CAN in an allogenic Fisher-
Lewis rat RTx model and to measure urinary cross-link to
assess its relationship with development of CAN.
2. Materials and Methods
2.1. Animals. Male inbred Fisher (F334, RT11v1) and Lewis
(LEW, RT11) rats weighing 250–300 g were purchased from
Harlan, UK. All experiments were performed in accordance
with the protocols of the Animals (Scientific Procedures) Act
1986 and approval from the Home Office (UK).
2.2. Rat Renal Transplant Model. The left donor kidney was
retrieved from the Fisher or Lewis donor rats and trans-
planted into Lewis rats, thereby generating the Fisher-Lewis
allografts and Lewis-Lewis isografts, respectively. Under
isoflurane inhalation anaesthesia, through amidline incision,
the left kidney was retrieved with a segment of aorta and
inferior venacava and their upper ends were ligated with 3/0
vicryl. The kidneys were perfused in situ with University of
Wisconsin solution by cannulation of infrarenal aorta and
preserved in the same solution at 4∘C. In the recipients,
left native nephrectomy and skeletonisation of abdominal
aorta and inferior venacava were performed. With the aid
of an operating microscope, an end-to-side anastomosis was
performed between the aortic and inferior venacaval (IVC)
conduits of the donor kidney to the recipient abdominal
aorta and IVC, respectively, using 10/0 prolene suture. The
bladder cuff attached to the donor ureter was anastomosed
to the dome of the recipient bladder. Intravenous fluids were
administered during both donor and recipient surgery to
maintain systemic blood pressure ensuring adequate perfu-
sion of the donor kidney and adequate reperfusion of the
recipient kidney. All recipient rats were given cyclosporine
(Novartis, UK) 5mg/kg s.c. for 10 days, which was followed
by right native nephrectomy.
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Figure 1: Glutamine (P1) and lysine (P2) residues of proteins are
linked together by TG2 in presence of Ca+2 leading to the formation
of 𝜀(𝛾-glutamyl)-lysine cross-link.
Transplanted kidneys were harvested when an animal’s
physical condition indicated the development of uraemia, as
reflected by a decrease in body weight and physical condition
in accordance with Home Office Project License or after 52
weeks. The average study duration for the isografts was 51
weeks (𝑛 = 5) and for the allografts 42 weeks (𝑛 = 7) without
reaching a statistical difference. Portions of the kidneys were
snap frozen in liquid nitrogen and stored at −150∘C for
immunohistochemical staining and messenger ribonucleic
acid (mRNA). Other samples were fixed in 4% formalin and
3% phosphate buffered glutaraldehyde for histological and
electron microscopic evaluation, respectively.
2.3. Functional Measurements. Serum creatinine, creatinine
clearance, protein excretion, and blood pressure were mea-
sured at 8 weekly intervals as described previously [25].
Albuminuriawasmeasured by a rat albuminELISA (enzyme-
linked immunosorbent analysis) (BiogNosis, Halisham, UK).
2.4. Histology. Formalin-fixed, paraffin-embedded tissues
were sectioned, stained with Masson’s trichrome, examined
by light microscopy, and analysed by multiphase image
analysis [26]. The tubular scarring index was determined
as a ratio of extracellular matrix to cell volume. Tubular
dilationwas assessed from the tubular lumen area and tubular
atrophy was assessed from the tubular cell area. Kidney tissue
stored in 3% phosphate buffered glutaraldehyde was fixed in
1% aqueous osmium tetroxide, blocked in epoxy resin, and
subjected to transmission electron microscopy [27].
2.5. TG2 Activity Assay. Total TG2 enzyme activity was
measured by calcium (Ca2+) dependent incorporation of
[1,4,-14C] putrescine into N󸀠,N󸀠󸀠-dimethylcasein. The tis-
sue homogenates were incubated (20 minutes, 37∘C) with
[1,4,-14C] putrescine (2.5 nM, 3.97 mice/mmol; Amersham
International, Little Chalfont, UK), dithiothreitol (3.8mM),
calcium chloride (2.5mM), and dimethylcasein (5mg/mL).
Homogenate was spotted onto 1 cm2 filter papers and pre-
cipitated with ice-cold 10% (wt/vol) trichloroacetic acid.
After washing, the putrescine incorporation into precipitated
protein was determined by scintillation counting. Results
were then corrected to U/mg/protein. 1 unit (U) of activity
was equivalent to 1 nmol putrescine incorporated per hour
at 37∘C [28].
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2.6. Immunolocalisation of TG2 and 𝜀(𝛾-Glutamine)-Lysine
Cross-Link. The distribution of immunoreactive TG2
and 𝜀(𝛾-glutamine)-lysine cross-link was determined
by immunohistochemistry and quantified by immuno-
fluorescence. 10𝜇m cryostat sections obtained from tissue
stored in liquid nitrogen were cut (−12∘C), air dried (37∘C),
and blocked in washing buffer (10mM EDTA, protease
inhibitor cocktail, 5% BSA, 0.01% triton X-100 + 5% normal
horse serum) for 60 minutes at room temperature. Washed
sections were incubated with a primary monoclonal, mouse
antibody at a dilution of 1 : 20 for TG2 (TgII Ab-2, TG100,
Neomakers, Fremont, CA, USA) for 12 hours at 4∘C.
The sections were fixed in ice cold acetone for 5 minutes
and incubated for 2 hours with an anti-mouse secondary
antibody (1/50 dilution in PBS containing 3% BSA) tagged
with fluorescein IgG (FITC) (T0116 (H+L).The sections were
mounted in Vectashield hardest fluorescent mounting media
with DAPI (H-1500, Vector, Burlingame, US).
For immunolocalisation of cross-link, a primary mono-
clonalmouse antibody at a dilution of 1 : 20 for 𝜀(𝛾-glutamyl)-
lysine (clone 81D4, Covalab, Lyon, France) and an anti-mouse
secondary antibody (1/50 dilution in PBS containing 3%BSA)
tagged with fluorescein IgG (FITC) (T0116 (H+L), Vector,
UK) were used by following the steps described above.
2.7. Quantification of TG2 and 𝜀(𝛾-Glutamyl)-Lysine Cross-
Link. Quantification was performed by viewing on a fluores-
cence Olympus BX61 microscope. Either 10 glomeruli (×400
magnification) or 10 overlapping tubulointerstitial fields were
visualised (×100 magnification) per section, analysed by
image analysis software (AnalySIS 3.2 software, Olympus Soft
Imaging Systems, GmBH, Munster, Germany).
TG2 and cross-link fluorescencewere quantified by three-
phase image analysis. Results were expressed as a ratio of
FITC stain (green) to nuclear DAPI stain (blue) areas.
2.8. Northern Blot. Total TG2 ribonucleic acid (RNA) was
extracted using Trizol (Gibco, UK) and subjected to North-
ern blot analysis using the Bam 400 TG2 complementary
deoxyribonucleic acid probe. Autoradiographs were quanti-
fied by scanning densitometry (Molecular Analyst version
4 software; Biorad, Hemel Hempstead, UK). Densitometry
values were corrected for loading using the house keeping
gene cyclophilin [29].
2.9. Urinary 𝜀(𝛾-Glutamyl)-Lysine Cross Link. 𝜀(𝛾-glutamyl)-
lysine dipeptide was measured in urine following protein
precipitation using 10% trichloroacetic acid in acetone and
exhaustive proteolytic digestion by incubation with sub-
tilisin, pronase E, carboxypeptidase (Sigma Aldrich, UK),
and leucine amino peptidase and prolidase (NBS Bio-
logicals, UK). Following fractionation of the freeze-dried
residue after resuspension in lithium citrate and postcolumn
derivatisation in ninhydrin, samples were read at 570 nm
with a retention time of 77 minutes using cation-exchange
high performance liquid chromatography (EzChomm Elite
software; Biochrom, Cambridge, UK) using a reference to
a 10 nm/20𝜇L 𝜀-(𝛾-glutamyl)-lysine calibration standard.
2.10. Statistical Analysis. Data analysis was carried out on
an intention-to-treat basis and analysed and presented using
GraphPad Prism 5 (GraphPad Software 2236, CA, USA).
Values are presented as means ± S.E.M. Serial longitudinal
measurements were compared by two-way ANOVA repeated
measures (mixed model) with Bonferroni’s post hoc test.
Terminal tissue data was compared using the nonparametric
Mann-Whitney 𝑈 test. Significant difference was assigned
when 𝑃 < 0.05.
3. Results
3.1. Functional Measurements. The allografts were hyper-
tensive at 2 weeks post-RTx and had a higher systolic
(Figure 2(a)), diastolic, and mean blood pressure than the
isografts throughout the study. At termination, the systolic
blood pressure was significantly higher in the allografts than
the isografts (159 ± 11 versus 124 ± 5mmHg, 𝑃 < 0.01).
The isografts showed a slight increase in urinary protein
excretion over the study period while the allografts showed
a marked progressive rise in proteinuria of some 20-fold
(Figure 2(b)). At termination, urinary protein excretion from
the allografts was 8-fold higher than the isografts (303 ± 80
versus 37 ± 17mg/24 h, 𝑃 < 0.005) together with a 15-fold
higher urinary excretion of albumin (60.7 ± 19 versus 4.1 ±
1.5mg/24 h, 𝑃 < 0.01).
Serum creatinine fell and creatinine clearance increased
in the early post-RTx period in both isografts and allografts,
reaching a maximum after 10 weeks (Figure 2(c)). In the iso-
grafts, creatinine clearancewas stable for the remainder of the
study.However, in the allografts creatinine clearance declined
progressively (Figure 2(d)), together with a marked rise in
serum creatinine. At termination, creatinine clearance in the
allografts was approximately 30% of the creatinine clearance
in the isografts (0.62 ± 0.18 versus 1.57 ± 0.19mL/min, 𝑃 <
0.01) together with a 3-fold higher serum creatinine (194 ±
48 versus 60 ± 5 𝜇mol/L, 𝑃 < 0.01).
3.2. Masson’s Trichrome Stain. Representative fieldsof kidney
sections stained with Masson’s trichrome showed normal
glomerular (Figure 3(a)) and tubular (Figure 3(b)) histology
without any evidence of ECM expansion, tubular dilatation,
or arteriolar intimal proliferation in isografts (Figure 3(c)).
The allografts showed evidence of glomerulosclerosis (Fig-
ure 3(d)), a marked expansion of the ECM, and extensive
tubular dilatation and atrophy (Figure 3(e)) together with
concentric proliferation of the arteriolar intima (Figure 3(f)).
The tubular scarring index was 15-fold higher in the allografts
than the isografts (33.9 ± 7.5 versus 2.38 ± 0.18, 𝑃 < 0.01).The
allografts showed a 6-fold increase in the area of the tubular
lumen (18.4 ± 4.2 versus 3.2 ± 0.4% field, 𝑃 < 0.02) together
with a marked decrease in the area of tubular cells (54 ± 5.1
versus 91.2 ± 0.7% field, 𝑃 < 0.01).
3.3. Electron Microscopy. Representative electron micro-
graphs showed a fenestrated endothelial lining in the
glomerular capillary, unexpanded mesangium, normal
glomerular basement membrane, and intact podocytic foot
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Figure 2: Serial measurements of (a) systolic blood pressure, (b) urinary protein, (c) serum creatinine, and (d) creatinine clearance for
isografts and allografts. Results were expressed as mean ± SEM (∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001).
processes in the isografts (Figure 4(a)). The allograft showed
evidence of subendothelial deposits and formation of a new
glomerular basement membrane together with the loss of
fenestrated endothelium and effacement of podocytic foot
processes (Figure 4(b)).
3.4. Total TG Enzyme Activity. Total TG enzyme activity,
measured in renal homogenates using 14C putrescine as the
substrate in the presence of calcium, was significantly higher
in the allografts than the isografts (1.09 ± 0.13 nmol/h/mg
protein versus 0.41 ± 0.03 nmol/h/mg protein, 𝑃 < 0.05).
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Figure 3: A representative field is shown from terminal kidney tissue of a glomerulus (a), the tubulointerstitium (b), and an arteriole (c)
from an isograft and a glomerulus (d), the tubulointerstitium (e), and an arteriole (f) from an allograft. Sections were stained with Masson’s
trichrome and visualised using ×20 objective.
3.5. TG2 Distribution and Quantification. Basal fluorescence
for TG2 protein in kidneys obtained from control Fisher and
Lewis rats was low, with no significant difference for either
glomerular or tubulointerstitial compartments.The allografts
showed markedly greater fluorescence for both glomerular
(Figures 5(b) and 5(a)) and tubulointerstitial fields (Figures
5(d) and 5(c)), indicating an upregulation of TG2 protein in
the allografts. In the isografts at termination, TG2 fluores-
cence remained similar to values obtained from control Lewis
rats. Kidneys from allografts showed amarked increase in the
FITC/DAPI ratios for TG2 protein (glomerulus: 64.55 ± 17.61
versus 2.11 ± 0.17, 𝑃 < 0.001, Figure 5(e), and interstitium:
13.72 ± 1.62 versus 3.19 ± 0.44, 𝑃 < 0.001, Figure 5(f))
compared to the isografts, indicating heightened TG2 activity
in the extracellular region. A significant, positive linear
correlation could be demonstrated between tubulointerstitial
TG2 and tubulointerstitial fibrosis (𝑟2 = 0.4016, 𝑃 < 0.05).
3.6. 𝜀(𝛾-Glutamyl)-Lysine Cross-Link Distribution and Quan-
tification. Representative examples are shown for glomerular
(Figures 5(h) and 5(g)) and tubulointerstitial fields (Figures
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Figure 4: Representative examples of electron micrographs of
glomerulus (×7,000) showing (a) isograft with normal glomerular
architecture (E: endothelial cell; P: podocytes; Lumen: capillary
lumen) and (b) allograft showing new basement membrane (BM),
subendothelial deposit (D), mesangial expansion (M), and efface-
ment of foot process (P).
5(j) and 5(i)) for the 𝜀(𝛾-glutamyl)-lysine cross-link for
isografts and allografts at termination. Basal fluorescence
for the 𝜀(𝛾-glutamyl)-lysine cross-link obtained from control
Fisher and Lewis rats was low in both glomerular and tubu-
lointerstitial compartments. Control Fisher rats showed a sig-
nificantly lower level of fluorescence in the glomerulus than
control Lewis rats although therewas no significant difference
in the tubulointerstitial compartment. In the isografts, at
termination, 𝜀(𝛾-glutamyl)-lysine fluorescence was similar to
control kidneys. The allografts, however, showed a 10-fold
increase in 𝜀(𝛾-glutamyl)-lysine fluorescence in the glomeru-
lus (21.75 ± 7.21 versus 1.98 ± 0.37, 𝑃 < 0.005) (Figure 5(k))
and an 80-fold increase in the tubulointerstitium (36.96 ±
17.06 versus 1.88 ± 2, 𝑃 < 0.05) (Figure 5(l)). A significant
positive linear correlation could be demonstrated between
tubulointerstitial 𝜀(𝛾-glutamyl)-lysine and tubulointerstitial
fibrosis (𝑟2 = 0.5541, 𝑃 < 0.02).
3.7. Urinary 𝜀(𝛾-Glutamyl)-Lysine Cross-Link. Total 𝜀(𝛾-
glutamyl)-lysine excretion in the isograft was 25.9 ±
1.5 nmol/24 h two weeks after transplant and remained
essentially unchanged over the study duration (Figure 6(a)).
Total 𝜀(𝛾-glutamyl)-lysine excretion from the allograft was
significantly higher at 57.2 ± 4.1 nmol/24 h (𝑃 < 0.05),
increasing by 9-fold to 534.2 ± 198.4 nmol/24 h at
termination. Urinary total 𝜀(𝛾-glutamyl)-lysine showed
a positive linear correlation with urinary protein excretion
(𝑟2 = 0.4133,𝑃 < 0.0001). At termination, total 𝜀(𝛾-glutamyl)-
lysine excretion showed a positive linear correlation with
the level of tubulointerstitial TG2 protein measured by
immunofluorescence (𝑟2 = 0.5707, 𝑃 < 0.05) (Figure 6(b)).
3.8. Northern Blot. Northern blot analysis showed a vis-
ible band for TG2 mRNA (3.5 kb) derived from renal
homogenates obtained from the allografts, which was absent
in the renal homogenates derived from the isografts. Using
cyclophilin as the loading control (1.8 kb), a 20-fold increase
in the volume density of kidney TG2 mRNA was detected in
the allografts compared to the isografts (6,523 ± 327 versus
328 ± 77, 𝑃 < 0.001) (Figure 7).
4. Discussion
Our study has demonstrated an upregulation of TG2 pathway
in the Fisher-Lewis rat RTx model of CAN. Kidneys from
control Fisher and Lewis rats contained a similar amount of
TG2 protein and 𝜀(𝛾-glutamyl)-lysine cross-link in the tubu-
lointerstitium. However, the control Fisher rats had lower
levels of the 𝜀(𝛾-glutamyl)-lysine cross-link in the glomeruli,
which, in the presence of a similar level of TG2 protein,
indicated a lower level of glomerular TG2 enzyme activity.
No change in the renal TG2 pathway could be detected in
the isograft for up to 1 year after RTx. In marked contrast,
the allografts showed upregulation of the TG2 enzyme and
its cross-link product. Although collagen can autofluoresce,
good negative controls with very low background were
obtained for the FITC immunofluorescence used to quantify
either TG2 protein or the cross-link using cryostat sections.
None of the quantified FITC immunofluorescence could be
attributed to collagen. Similar results were obtained using
Texas red as the fluorochrome.
Total TG2 enzyme activity was increased in kidney
homogenates, while mRNA analysis indicated an increase
in TG2 transcription. Increased TG2 transcription is the
most likely explanation for the increase in TG2 protein
which shows greater enzymatic activity to generate more
cross-link product. An increase in TG2 was demonstrated in
extracellular compartments of both glomeruli and the tubu-
lointerstitium where the enzyme is activated by extracellular
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Figure 5: Representative fields of immunofluorescence staining (FITC, green) for transglutaminase type 2 protein ((a)–(d)) and 𝜀(𝛾-
glutamyl)-lysine ((g)–(j)) for the Lewis- (L-) Lewis (L) isograft and Fisher- (F-) Lewis (L) allograft in both glomerular and tubulointerstitial
areas. Transglutaminase type 2 protein ((e)–(f)) and 𝜀(𝛾-glutamyl)-lysine cross-link ((k)–(l)) were quantified by multiphase image analysis
and expressed as the FITC/DAPI ratio for L-L isografts and F-L allografts at termination and for control F and L rats. Vertical bars indicate
± SEM.
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calcium [30]. In the glomerulus, TG2 was present, predom-
inantly in the mesangium, associated with grossly scarred
glomeruli. With more severe damage, TG2 was also detected
in periglomerular areas togetherwith periglomerular fibrosis.
The tubulointerstitial staining of TG2 was largely peritubular,
with expanded interstitium displaying more intense staining
similar to findings observed in human kidney transplant
biopsies [24]. El Nahas et al. investigated TG2 and its cross-
link product in 23 human kidney allografts during the early
posttransplantation period, 8 of which developed chronic
allograft nephropathy [24]. A more recent clinical study
showed increased TG2 mRNA in protocol biopsies from
kidney transplant patients who went on to develop CAN, 6
months after RTx [31].
An association between renal fibrosis and TG2 was first
demonstrated in the rat following 5/6 subtotal nephrectomy
[21]. Following RTx, ischaemia-reperfusion injury followed
by immunological injury could initiate events leading to the
upregulation of TG2 transcription within the glomeruli. Vas-
cular injury and atherosclerosis are associated with smooth
muscle cell proliferation and the upregulation of TG2 [32,
33]. Proliferating parietal epithelial cells, monocytes, and
fibroblasts possibly originating from the transdifferentiation
of glomerular epithelial cells [34]may also be a source of TG2.
The distribution of TG2, in peritubular and periglomeru-
lar spaces, is similar to the distribution of myofibroblasts,
as well as the ECM. Although myofibroblasts contribute to
production of ECM, it is the perturbation of TG2 production
and its release by tubular cells which leads to the enhanced
levels of 𝜀(𝛾-glutamyl)-lysine found in renal scarring studies
[21, 29]. TG2 is considered to be an ECM-modulating enzyme
linked to the actions of transforming growth factor-𝛽1 (TGF-
𝛽1) in the scarred kidney [35, 36]. TG2 may play a key role
in matrix storage and in the activation of TGF-𝛽1, through
the cross-linking of the large latent TGF-𝛽1-binding protein
to the ECM [37]. The excessive accumulation of TG2 within
renal epithelial cells can also lead to cell death through
extensive intracellular cross-linking of proteins in the absence
of apoptosis. Therefore, the level of TG2 expression and level
of activation determine its beneficial effects on healing or
detrimental death signals [29, 38].
The allograft also contained elevated levels of the cross-
link product, 𝜀(𝛾-glutamyl)-lysine, in the tubulointerstitium
which showed a significant linear correlation with the devel-
opment of tubulointerstitial fibrosis. The urinary cross-link
expressed permilligram protein doubled from approximately
0.7 to 1.6 nmol/mg; however, we have no data to support
the origin of the cross-link identified in the urine. While
systemic circulating protein such as albumin remains a
possibility this would seem less likely and would need to
be intramolecular cross-linking since intermolecular cross-
linking would greatly increase molecular weight and reduce
oncotic activity. Similar observations have beenmade in both
human chronic kidney disease and experimental rat models
of chronic kidney disease [21, 23]. TG2 measurements in
terminal kidney tissue were supported by the analysis of
total 𝜀(𝛾-glutamyl)-lysine cross-link product excreted in the
urine. At 2 weeks after RTx, total urinary 𝜀(𝛾-glutamyl)-
lysine excretion from the allografts was already double that
detected from the isograft and showed a progressive increase
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Figure 7: Northern Blot of the renal homogenates for TG2 mRNA. (a) Histogram shows renal TG2 mRNA corrected for loading in arbitrary
units of optical density. Vertical bars indicate ±SEM. (b) Autoradiograph showing using cyclophilin as the loading control, isografts (lanes
1–3) and allografts (lanes 4–7).
throughout the study. At termination, total 𝜀(𝛾-glutamyl)-
lysine excreted in the urine gave a significant positive linear
correlation with TG2 protein detected in the kidney. As
far as we are aware, this represents the first report of total
𝜀(𝛾-glutamyl)-lysine excretion measured in the urine of any
animal species.
Interventional studies targeting fibrosis in CAN have
previously been directed at modifying the synthesis or the
breakdown of matrix proteins [13], inhibition of matrix
protein cross-linking, and thereby matrix deposition, may
represent a viable alternative. TG inhibitors have been
demonstrated to both reduce glucose-stimulated, matrix
accumulation in proximal tubular cells in vitro [39] and
reduce the development of kidney scarring in vivo in the
hypertensive rat following subtotal nephrectomy [26]. Huang
et al. have demonstrated inhibition of TG2 with NTU281
in uninephrectomized streptozotocin-induced diabetic rats,
where TG2 inhibition significantly reversed the increased
serum creatinine and albuminuria in the diabetic rats and
also led to fivefold decrease in glomerulosclerosis and a
sixfold reduction in tubulointerstitial scarring [40].
In summary, tubulointerstitial fibrosis is a common final
pathway of CAN. In this study, we demonstrated an associa-
tion between the TG2 enzyme and its cross-link product 𝜀(𝛾-
glutamyl)-lysine and the development of CAN in the Fisher-
Lewis allografts, which has not been studied in animalmodels
of CAN previously. Our report on the urinary excretion of
cross-link product 𝜀(𝛾-glutamyl)-lysine in this model is the
first of its kind.Thus ourmodel provides valuable insight into
the inhibition of TG2 by using new pharmacological agents to
slow the progression of CAN and the application of urinary
𝜀(𝛾-glutamyl)-lysine as a useful tool for monitoring CAN.
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